Floatz logo

CIS-DIAMMINEDICHLOROPLATINUM II

Primary Peritoneal Cavity Cancer

GOG FoundationSmall moleculePhase 3Active
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
71/ 100
Competitive Position
89/ 100

Competitive context

153 Active assets in the Primary Peritoneal Cavity Cancer cohort.

Asset / SponsorPhaseRating
Carboplatin
University of Washington
Phase 3BBB
Hycamtin
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
Inno-206
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3BBB
PEGFILGRASTIM
TORL Biotherapeutics, LLC
Phase 2/3BBB
Inno-206
Case Comprehensive Cancer Center
Phase 3BBB

View all 50 →

Same molecule, other indications

CIS-DIAMMINEDICHLOROPLATINUM II is also rated in:

squamous cell lung carcinomaDormant
BBB
Indicative ·
78 / 100
View asset →
adenocarcinomaDormant
BBB
Indicative ·
76 / 100
View asset →
Nasal and Nasal-type NK/T-cell LymphomaDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →